Close Menu

It's not exactly uplifting, but this article from the Wall Street Journal reports on the fate of the pharmaceutical industry. (We'd say it places it somewhere between "embattled" and "dire.") While a number of blockbuster drugs are coming off patent, fewer and fewer drugs have gone on the market, and -- at least according to pharma execs -- FDA is getting increasingly picky about handing out approvals.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.